Ms Hannah Beilby

Research Officer

Centre for the Business and Economics of Health
Faculty of Business, Economics and Law


Hannah started working as Research Officer at the Centre for the Business and Economics of Health (CBEH) under Professor Brenda Gannon after a year in international development and over five years of experience working within the pharmacy sector.

She is currently undertaking economic evaluations and modelling of clinical trials in diverse clinical areas such as ageing, paediatric emergency care, infectious and chronic disease.

Research Interests

  • Health Economics
  • Applied Econometrics
  • Antibiotic Resistance

Research Impacts

Hannah's professional and academic successes include the results of her honours research into novel drug targets for breast cancer, which contributed to a published paper in a respected medical journal, along with poster presentations in both domestic and international conferences. This work was done with the Calcium Signalling in Cancer Research team during her undergraduate at the Pharmacy Australia Centre of Excellence (PACE).


  • Bachelor of Pharmacy (Honours Class 2A), The University of Queensland
  • Master of Health Economics, The University of Queensland


View all Publications


Journal Article

Conference Publication

  • Azimi, Iman, Beilby, Hannah, Davis, Felicity M., Roberts-Thomson, Sarah J. and Monteith, Gregory R. (2012). Altered purinergic receptor calcium signalling associated with hypoxia in MDA-MB-468 breast cancer cells. In: Joint ASCEPT-APSA 2012 Conference: Final Program and Abstract Book. Joint ASCEPT-APSA 2012 Conference, Medication Safety, Sydney, Australia, (77-77). 2 - 5 December 2012.

  • Azimi, I., Beilby, H., Davis, F. M., Roberts-Thomson, S. J. and Monteith, G. R. (2012). Role of hypoxia-induced epithelial-mesenchymal transition in calcium signalling in breast cancer cells. In: Abstracts of 24 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin Ireland, (156-156). 6-9 November 2012. doi:10.1016/S0959-8049(12)72301-8